Sanofi sees higher earnings as blockbuster skin drug soars

In 2021, blockbuster eczema treatment Dupixent was the main growth driver for French Sanofi, and the company forecasts a bright 2022 for the drug.
Photo: VIOLETA SANTOS MOURA/REUTERS / X07448
Photo: VIOLETA SANTOS MOURA/REUTERS / X07448
By Tim Loh, bloomberg

Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading